From Clinical Care Options, Tanios Bekaii-Saab, MD, reviews key data from studies of gastrointestinal cancer treatment presented at ASCO 2019.
Todd M. Bauer, MD; Marcia S. Brose, MD, PhD; and George D. Demetri, MD, discuss the latest data on TRK inhibitors in solid tumors with NTRK fusions.
Drs. Todd M. Bauer, Giuseppe Giaccone, Axel Grothey, John L. Marshall, and Michael J. Pishvaian discuss the latest data on 10 key clinical biomarkers in solid tumors.
Novel KRASG12C inhibitor AMG 510 was tolerable and showed preliminary antitumor activity in KRASG12C-positive tumors, including NSCLC, as reported by CCO from ASCO 2019.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.